Skip to content Skip to footer
Subscribe Now
INSIGHTS+

EMA Marketing Authorization of New Drugs in December 2025   

Shots:  Innovation in drug development continues to reshape patient care across dermatology, cardiology, immunology, oncology, respiratory medicine, and infectious diseases, as regulatory momentum in Europe remains strong toward the end of 2025. Recent EMA actions highlight how advanced biologics, precision small molecules, and next-generation vaccines are translating clinical breakthroughs into real-world impact.  In December 2025, the EMA…
January 20, 2026

Read more

EVENTS

Get Tailored Highlights from the 44th Annual J.P. Morgan Healthcare Conference

Shots: The 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026 in San Francisco, California, stands as the most influential healthcare investment event on the global calendar. Widely recognized as the industry’s premier forum, the conference brings together global biopharma leaders, high-growth innovators, cutting-edge technology companies, and the investment community shaping the future…
December 30, 2025

Read more

EVENTS

Evolution Summit By Marcus Evans | 20-21 January 2026 | Four Seasons Hotel | Westlake Village, CA, USA

The Evolution Summit is an invitation-only, premium Summit bringing leading clinical trial executives and innovative suppliers and solution providers together. The Summit’s content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. This is an exclusive, invitation-only event. To learn more…
December 24, 2025

Read more

EVENTS

PharmaMarketing Summit By Marcus Evans | 22-23 January 2026 | Four Seasons Hotel | Westlake Village, CA, USA

The PharmaMarketing Summit is an invitation-only, premium Summit bringing leading pharmaceutical marketing executives and innovative suppliers and service providers together. The Summit’s content is aligned with key pharmamarketing challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. This is an exclusive, invitation-only event. To learn more or…
December 24, 2025

Read more

VIEWPOINTS

Inside Anavex’s Alzheimer’s Strategy: Dr. Christopher Missling on Blarcamesine, SIGMAR1, and Precision Medicine 

Shots:   Neurodegenerative care is at a pivotal inflection point, shifting from symptomatic relief to strategies that restore cellular resilience. Blarcamesine (ANAVEX 2-73) advances this upstream approach by activating SIGMAR1 to rebalance autophagy, targeting a core driver of neurodegeneration  Phase IIb/III findings demonstrated a statistically significant slowing of cognitive decline, with the most pronounced benefit seen in patients carrying the…
December 22, 2025

Read more

MAGAZINE

PharmaShots Magazine-December-2025 Edition

In a healthcare environment defined by rapid scientific leaps and rising patient expectations, two influential forces are quietly reshaping the industry’s very foundation: Key Opinion Leaders (KOLs) and Patient Advocacy Groups (PAGs) Once background contributors, they have emerged as pivotal architects of modern healthcare, steering clinical decisions, shaping scientific narratives, influencing policy, and ensuring that patient voices are not just heard…
December 11, 2025

Read more

INSIGHTS+

The US FDA New Drug Approvals in November 2025 

Shots:  Innovation surged in November, with cutting-edge science and strategic collaborations reshaping the drug development landscape across oncology, renal disease, hereditary conditions, and more  The US FDA cleared five standout therapies, including Bayer’s Hyrnuo (Sevabertinib), UCB’s Kygevvi (Doxecitine + Doxribtimine), and Arrowhead’s Redemplo, underscoring a month of meaningful clinical progress  November 2025 closed with five approvals, matching last year’s total, signaling sustained momentum and a steady…
December 9, 2025

Read more

VIEWPOINTS

A New Era for Myeloma Patients: Regeneron’s Karen Rodriguez Lorenc on Lynozyfic’s Rising Global Impact 

Shots:  Lynozyfic is emerging as a standout in heavily pre-treated multiple myeloma. In the pivotal LINKER-MM1 trial, it delivered early, deep, and durable responses, offering renewed hope for patients with limited options. Its response-adapted dosing regimen further reduces treatment burden and enhances convenience  Regeneron is accelerating progress with a broad development strategy, advancing Lynozyfic across multiple therapy lines, combination regimens, precursor conditions, and global markets. The program…
December 8, 2025

Read more

VIEWPOINTS

Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology 

Shots:  Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells  Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…
December 3, 2025

Read more

Load more